The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
Open accessAbstract
PURPOSE: To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema (DME). DESIGN: Two randomized, multicenter, masked, sham-controlled, phase III clinical trials with identical protocols were conducted. Data were pooled for analysis. PARTICIPANTS: Patients (n = 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen equivalent, and central retinal thickness (CRT) of ≥300 μm by optical coherence tomography. METHODS: Patients were randomized in a 1:1:1 ratio to study treatment with DEX implant 0.7 mg, DEX implant 0.35 mg, or sham procedure and followed for 3 years (or 39 months for patients treated at month 36) at ≤40 scheduled visits. Patients who met retreatment eligibility criteria could be retreated no more often than every 6 months. MAIN OUTCOME MEASURES: The predefined primary efficacy endpoint for the United States Food and Drug Administration was achievement of ≥15-letter improvement in BCVA from baseline at study end. Safety measures included adverse events and intraocular pressure (IOP). RESULTS: Mean number of treatments received over 3 years was 4.1, 4.4, and 3.3 with DEX implant 0.7 mg, DEX implant 0.35 mg, and sham, respectively. The percentage of patients with ≥15-letter improvement in BCVA from baseline at study end was greater with DEX implant 0.7 mg (22.2%) and DEX implant 0.35 mg (18.4%) than sham (12.0%; P ≤ 0.018). Mean average reduction in CRT from baseline was greater with DEX implant 0.7 mg (-111.6 μm) and DEX implant 0.35 mg (-107.9 μm) than sham (-41.9 μm; P < 0.001). Rates of cataract-related adverse events in phakic eyes were 67.9%, 64.1%, and 20.4% in the DEX implant 0.7 mg, DEX implant 0.35 mg, and sham groups, respectively. Increases in IOP were usually controlled with medication or no therapy; only 2 patients (0.6%) in the DEX implant 0.7 mg group and 1 (0.3%) in the DEX implant 0.35 mg group required trabeculectomy. CONCLUSIONS: The DEX implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA. The safety profile was acceptable and consistent with previous reports.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Self-citationMitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Self-citationThe Prevalence of Diabetic Retinopathy Among Adults in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.552 · Cited by 1,148
Haller, J. A., Bandello, F., Belfort, R., Blumenkranz, M. S., Gillies, M., Heier, J., Loewenstein, A., Yoon, Y.-H., Jacques, M.-L., Jiao, J., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.032 · Cited by 1,068
Self-citationBrown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Self-citationMiyamoto, K., Khosrof, S., Bursell, S.-E., Rohan, R., Murata, T., Clermont, A. C., Aiello, L. P., Ogura, Y., & Adamis, A. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10836 · Cited by 788
Photocoagulation for Diabetic Macular Edema
Aiello, L. M., & Ferris, F. L. (1987) · Archives of Ophthalmology · doi:10.1001/archopht.1987.01060090021004 · Cited by 733
Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant
Chang-Lin, J.-E., Attar, M., Acheampong, A. A., Robinson, M. R., Whitcup, S. M., Kuppermann, B. D., & Welty, D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5285 · Cited by 590
Self-citationElman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 573
Diabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
Campochiaro, P. A., Brown, D. M., Pearson, A., Chen, S., Boyer, D., Ruiz-Moreno, J., Garretson, B., Gupta, A., Hariprasad, S. M., Bailey, C., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.030 · Cited by 517
Self-citationAssociation of Vitreous Inflammatory Factors with Diabetic Macular Edema
Funatsu, H., Noma, H., Mimura, T., Eguchi, S., & Hori, S. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.037 · Cited by 451
GILLIES, M., SUTTER, F., SIMPSON, J., LARSSON, J., ALI, H., & ZHU, M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.065 · Cited by 425
DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS
Boyer, D. S., Faber, D., Gupta, S., Patel, S. S., Tabandeh, H., Li, X.-Y., Liu, C. C., Lou, J., & Whitcup, S. M. (2011) · Retina · doi:10.1097/iae.0b013e318206d18c · Cited by 355
Self-citationThe Pathogenesis of Edema in Diabetic Maculopathy
Antcliff, R. J., & Marshall, J. (1999) · Seminars in Ophthalmology · doi:10.3109/08820539909069541 · Cited by 342
Haller, J. A. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.21 · Cited by 298
Antonetti, D. A., Wolpert, E. B., DeMaio, L., Harhaj, N. S., & Scaduto, R. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00740.x · Cited by 272
Ageing and the glomerular filtration rate: truths and consequences.
Glassock, R. J., & Winearls, C. G. (2009) · PubMed Central · Cited by 251
Tamura, H., Miyamoto, K., Kiryu, J., Miyahara, S., Katsuta, H., Hirose, F., Musashi, K., & Yoshimura, N. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0905 · Cited by 251
Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review
Kiddee, W., Trope, G. E., Sheng, L., Beltran-Agullo, L., Smith, M., Strungaru, M. H., Baath, J., & Buys, Y. M. (2013) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.08.003 · Cited by 192
Wang, K., Wang, Y., Gao, L., Li, X., Li, M., & Guo, J. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1541 · Cited by 134
Self-citationNehmé, A., Lobenhofer, E. K., Stamer, W. D., & Edelman, J. L. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-58 · Cited by 116
Aiello, L. P., Edwards, A. R., Beck, R. W., Bressler, N. M., Davis, M. D., Ferris, F. L., Glassman, A. R., Ip, M. S., & Miller, K. M. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.10.002 · Cited by 99
Differentiating Intraocular Glucocorticoids
Edelman, J. L. (2010) · Ophthalmologica · doi:10.1159/000315158 · Cited by 91
Trabecular Meshwork and Lens Partitioning of Corticosteroids
Thakur, A., Kadam, R. S., & Kompella, U. B. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.39 · Cited by 56
Cited by
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Mechanisms of macular edema: Beyond the surface
Daruich, A., Matet, A., Moulin, A., Kowalczuk, L., Nicolas, M., Sellam, A., Rothschild, P.-R., Omri, S., Gélizé, E., Jonet, L., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.006 · Cited by 708
Metadata
- Authors
- Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 121
- Issue
- 10
- Pages
- 1904-1914
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W1972102480
- Cited by
- 1,122
- References
- 29
- FWCI
- 88.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.